Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer

Anticancer Research

Volumn 32, Issue 6, 2012, Pages 2331-2336

  Kubo, Makoto ^a   Onishi, Hideya ^a   Kuroki, Syoji ^b   Okido, Masayuki ^c   Shimada, Kazuo ^d   Yokohata, Kazunori ^e   Umeda, Shuyo ^f   Ogawa, Takahiro ^g   Tanaka, Masao ^a   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Kuroki Breast Clinic   (Japan)

^c HAMANOMACHI HOSPITAL   (Japan)

^d Shimada Breast Surgery Clinic   (Japan)

^e FUKUOKA RED CROSS HOSPITAL   (Japan)

^f KYUSHU KOSEI NENKIN HOSPITAL   (Japan)

^g HARASANSHIN HOSPITAL   (Japan)

Author keywords

Aromatase inhibitor; Arthralgia; Breast cancer; Steroid hormone

Indexed keywords

ANASTROZOLE; LETROZOLE; PREDNISOLONE; ANTIINFLAMMATORY AGENT; AROMATASE INHIBITOR; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ANALGESIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; LOW DRUG DOSE; MORNING DOSAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT COURSE THERAPY; TREATMENT DURATION; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; MIDDLE AGED; MULTICENTER STUDY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; PREDNISOLONE; TRIAZOLES;

EID: 84864555869     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Dizdar O, Ozçakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y and Altundag K: Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27: 4955-4960, 2009.
2. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ and Pater JL; National Cancer Institute of Canada Clinical Trials Group MA.17: Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 25: 2006-2011, 2007.
3. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E and Bliss JM; Intergroup Exemestane Study: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369: 559-570, 2007.
4. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN and Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25: 486-492, 2007.
5. Din OS, Dodwell D, Wakefield RJ and Coleman RE: Aromatase inhibitor-induced arthralgia in early breast cancer: What do we know and how can we find out more? Breast Cancer Res Treat 120: 525-538, 2010.
6. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P and Bhatnagar A: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101-2109, 2003.
7. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ and Pater JL: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 349 : 1793-1802, 2003.
8. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM and van de Velde C; Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Engl J Med 350: 1081-1092, 2004.
9. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M and Wolfgang J; ABCSG and the GABG: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after two years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455-462, 2005.
10. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN and Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 353: 2747-2757, 2005.
11. Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D and Sismondi P: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17: vii10-14, 2006.
12. Donnellan PP, Douglas SL, Cameron DA and Leonard RC: Aromatase inhibitors and arthralgia. J Clin Oncol 19 : 2767, 2001.
13. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR and Neven P: Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26 : 3147-3152, 2008.
14. Boeddinghaus IM, Dowsett M: Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 79 : 85-91, 2001.
15. Dawson-Basoa M and Gintzler AR: Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal stimulation. Brain Res 757 : 37-42, 1997.
16. Burstein HJ and Winer EP. Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 25 : 3797-3799, 2007.
17. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY and Nabholtz JM: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 : 633-643, 2006.
18. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A and Hershman DL: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25: 3877-3883, 2007.
19. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR and Buzdar AU; ATAC Trialists' Group: Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9: 866-872, 2008.
20. Lintermans A and Neven P: Pharmacology of arthralgia with estrogen deprivation. Steroid 76 : 781-785, 2011.
21. Thorne C: Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 14: S11-19, 2007.
22. Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J and De Grève J:Tolerance to adjuvant letrozole outside of clinical trials. Breast 17: 376-381, 2008.
23. Briot K, Tubiana-Hulin M, Bastit L, Kloos I and Roux C: Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120 : 127-134, 2010.
24. Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W and Hershman DL: Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28: 1154-1160, 2010.
25. Morel B, Marotte H and Miossec P: Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis 66: 557-558, 2007.
26. Laroche M, Borg S, Lassoued S, De Lafontan B and Roché H. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. J Rheumatol 34 : 2259-2263, 2007.
27. Aitken RC: Measurement of feelings using visual analogue scales. Proc R Soc Med 62: 989-993, 1969.
28. Felson DT, Cummings SR: Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52: 2594-2598, 2005.
29. Avis N: Bailliere's clinical endocrinology and metabolism. In: The Evolution of Menopausal Symptoms. Burger H (ed.). Bailliere Tindall, London, 2004.
30. Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N and Hadji P: Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34 : 275-282, 2008.
31. Straub RH: The complex role of estrogens in inflammation. Endocr Rev 28: 521-574, 2007.
32. Henry NL, Pchejetski D, A'Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V and Stebbing J: Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case control study. Br J Cancer 103: 291-296, 2010.
33. Wassenberg S, Rau R, Steinfeld P and Zeidler H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52 : 3371-3380, 2005.